Tom Baladi is an accomplished scientist currently serving as Principal Scientist and Oligo Modality Lead at Lundbeck since November 2025, while also being a Co-Founder of LanteRNA since November 2021. Previously, Tom held the positions of Associate Principal Scientist and Senior Research Scientist at AstraZeneca from August 2020 to November 2025, focusing on oligonucleotide chemistry. Tom's academic contributions include postdoctoral fellowships at Chalmers University of Technology and Institut de Chimie de Nice, with a research emphasis on developing fluorescent base analogues and small molecules for cancer treatment, respectively. Additionally, Tom completed a PhD in Medicinal Chemistry (Oncology) at Université Paris-Saclay and has a strong foundation in organic synthesis backed by multiple degrees in organic chemistry from Ecole Nationale Supérieure de Chimie de Montpellier and Université Montpellier II.
This person is not in the org chart
This person is not in any teams
This person is not in any offices